1. Home
  2. GSIW vs TELA Comparison

GSIW vs TELA Comparison

Compare GSIW & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

N/A

Current Price

$30.02

Market Cap

33.5M

Sector

N/A

ML Signal

N/A

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$1.04

Market Cap

37.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
TELA
Founded
2016
2012
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
37.5M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
GSIW
TELA
Price
$30.02
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$2.00
AVG Volume (30 Days)
2.2K
199.0K
Earning Date
08-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.59
EPS
N/A
N/A
Revenue
N/A
$80,275,000.00
Revenue This Year
N/A
$10.23
Revenue Next Year
N/A
$14.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.84
52 Week Low
$0.05
$0.50
52 Week High
$36.90
$2.19

Technical Indicators

Market Signals
Indicator
GSIW
TELA
Relative Strength Index (RSI) 65.93 62.28
Support Level $0.11 $0.98
Resistance Level $32.25 $1.24
Average True Range (ATR) 0.79 0.15
MACD -0.62 0.04
Stochastic Oscillator 31.93 66.83

Price Performance

Historical Comparison
GSIW
TELA

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

Share on Social Networks: